Figure 7
Development of chronic pancreatitis induced by NOD1 ligand and a low-dose cerulein requires adaptive immune responses (a) C57BL6 mice and RAG1-deficient mice (RAG1−/−) were administered a low-dose cerulein for a total of three times, or FK565 followed by a low-dose cerulein for a total of three times as described in Figure 1. Mice received each regimen twice a week for a total of 14 times and then sera and pancreatic tissues were obtained. Total numbers of mice in each group were as follows; C57BL6 cerulein (CER): n=9, C57BL6 CER+FK565: n=9, RAG1−/− CER: n=9, RAG1−/− CER+FK565: n=9. Serum levels of amylase, pathological scores of the pancreas, pancreatic weight, pancreatic levels of hydroxyproline, and the numbers of α-SMA+ cells obtained from mice three hours after the last injection of cerulein. Results are expressed as mean±s.e.m. and are a pool of two independent experiments. *P<0.05, **P<0.01 as compared with C57BL6 mice treated with FK565 and cerulein. (b) Concentrations of cytokines and chemokines in pancreatic lysates were determined by ELISA. Levels of cytokines and chemokines in the pancreas are shown as values per 100 mg pancreatic tissue. Results are expressed as mean±s.e.m. **P<0.01, *P<0.05 as compared with C57BL6 mice treated with cerulein and FK565. (c) Representative picture of the pancreas tissue stained with H&E, anti-fibronectin and anti-SMA, magnification × 400. ELISA, enzyme-linked immunosorbent assay; H&E; hematoxylin and eosin; NOD1, nucleotide-binding oligomerization domain 1.
